业绩增速放缓 仙乐健康赴港筹钱

Core Viewpoint - Xianle Health has submitted an application for an IPO on the Hong Kong Stock Exchange, aiming to establish a dual capital platform "A+H" to adapt to future growth paths and capital structure adjustments [1] Group 1: Company Overview - Xianle Health, established in 1993, transitioned from pharmaceutical manufacturing to the nutrition and health food contract manufacturing (CDMO) sector in 2000 [4] - The company has expanded globally since 2016, acquiring German company Ayanda and gaining control of American company Best Formulations [4] - Xianle Health is currently the largest CDMO in China and the third largest globally in the nutrition and health food sector, with soft capsules and gummies accounting for over 70% of its revenue [4] Group 2: Financial Performance - Recent financial data shows a slowdown in revenue growth, with revenues of 3.582 billion yuan, 4.211 billion yuan, and 3.291 billion yuan for the first three quarters of 2023, 2024, and 2025 respectively [5] - Net profits for the same periods were 240 million yuan, 282 million yuan, and 56 million yuan, with a projected decline in net profit for 2025 by 53% to 69% due to asset impairment losses and strategic investments [5][6] - The company plans to use funds from the IPO to enhance product R&D, implement digital upgrades, and optimize production capacity [7] Group 3: Market Challenges - The CDMO model heavily relies on large client orders, making revenue stability vulnerable to brand strategy changes [4] - The lifecycle of popular health products is shortening, impacting the CDMO model's profitability, as upfront costs may not be recouped if products exit the market prematurely [7] - The company aims to transition from a "manufacturing service provider" to a "solution provider" to improve pricing power and mitigate pressure from downstream pricing [6]